Post transplant lymphoma occurs due to proliferation of which of the following cells?
## **Core Concept**
Post-transplant lymphoproliferative disorders (PTLD) are a well-recognized complication of solid organ transplantation and hematopoietic stem cell transplantation. These disorders arise due to the immunosuppression required for transplantation, leading to uncontrolled proliferation of lymphocytes. The underlying cause is often related to the reactivation of **Epstein-Barr Virus (EBV)** in the setting of immunosuppression.
## **Why the Correct Answer is Right**
The correct answer, **B cells**, is right because PTLD is primarily attributed to the proliferation of B lymphocytes. This proliferation is often driven by the reactivation of **EBV**, a virus that infects more than 90% of the global population at some point in their lifetime. In immunocompetent individuals, EBV infection is usually asymptomatic or causes self-limiting infectious mononucleosis. However, in the immunosuppressed state, such as post-transplant, EBV can reactivate and lead to uncontrolled B cell proliferation.
## **Why Each Wrong Option is Incorrect**
- **Option A:** T cells are not the primary cells involved in the pathogenesis of PTLD, although T cell lymphomas can occur post-transplant, they are less commonly associated with EBV.
- **Option C:** While plasma cells are mature B cells and can be involved in certain types of lymphoproliferative disorders, PTLD is specifically more related to the early stages of B cell development and proliferation, often driven by EBV.
- **Option D:** Natural Killer (NK) cells are a type of lymphocyte that can be involved in lymphoproliferative disorders, but they are not the primary cell type implicated in PTLD.
## **Clinical Pearl / High-Yield Fact**
A key clinical pearl is that **EBV-negative PTLD** tends to have a worse prognosis and is more commonly associated with **T cell** or **NK cell** malignancies. Clinicians should monitor EBV levels post-transplant as a surrogate marker for PTLD risk and consider reducing immunosuppression or other interventions if EBV levels rise significantly.
## **Correct Answer: B. B cells**